Mosaic Therapeutics in-licenses two clinical-stage oncology programs from Astex Pharmaceuticals for development as proprietary combination therapies

CEO

Thomas brings 25+ years’ experience in leadership positions across early drug development, commercialisation and life cycle management.
Previously CEO at Cimeio Therapeutics and former Global Haematology Franchise Head at Roche-Genentech.
He holds an MBA from the Kellogg School of Management at Northwestern University and a Bachelor of Science in Business Administration from the University of Wisconsin-Stout.

Board Chair

Ed was previously the first CEO and a board member of Autolus Therapeutics (NASDAQ:AUTL), and the former CEO of Resolution Therapeutics.
Within the Syncona life science team, Ed is involved in creation of new businesses and then fills executive roles within those companies to make them operational.
Ed was previously CEO of Biotica Ltd (Cambridge, UK), President & Chief Business Officer of BrainCells Inc (San Diego, CA), and VP, Business Development & Marketing at Tripos Inc (St Louis, MO).
Ed holds a degree and DPhil in Chemistry from the University of Oxford, and is a former Chairman of the BIA, the UK’s trade association for innovative life science companies.

Non-Executive Director

Laurence is a highly experienced biotech entrepreneur and leader, currently serving as advisor and board member to companies moving through growth phases, strategic inflections, and other formative stages
Laurence was previously CEO, President and a Board member at Decibel Therapeutics, leading the company through IPO in 2021 and a 2023 acquisition by Regeneron
Other roles have included: CEO of Warp Drive Bio (2018 merger with Revolution Medicines), former entrepreneur in residence at Third Rock Ventures (including CEO roles in portfolio companies), and CBO at Alnylam Pharmaceuticals
Laurence holds a PhD in Biochemistry from the University of London, and BA in Natural Sciences from Cambridge University

NON-EXECUTIVE DIRECTOR

Magda is a Partner of Syncona Investment Management Ltd.
Magda was previously an Associate Partner at McKinsey & Company where she specialised in pharmaceuticals Research & Development, portfolio management and Business Development and Licensing.
Magda holds a PhD in Bioengineering from Stanford University and was a postdoctoral fellow in Harvard Medical School’s Computational Health Informatics Programme.

CSO

Stephen brings 30 years of experience as a pharmaceutical scientist, senior executive, entrepreneur and investor.
He has been a Venture Partner at Samsara BioCapital (Palo Alto, CA) since 2019, and previously served as CSO, COO and Executive Director for over 10 years at Karus Therapeutics.
Prior to Karus, Stephen held scientific leadership positions in the UK, US and Canadian biotech industries, notably at Piramed Pharma, Tularik, BioChem Pharma and CRUK.
He has directed multiple small molecule therapeutics research programmes, primarily in cancer. Of note, he led the design, research and preclinical development of three small molecule cancer therapeutics, all completing phase I clinical studies: Pictilisib (pan-class I PI3K), KA2237/CVL-237 (selective PI3K-beta/delta), and KA2507 (HDAC6)
Stephen holds a PhD in Chemistry from the University of Liverpool, and is a Fellow of the Royal Society of Chemistry.

CO-FOUNDER

Mathew is a Senior Group Leader at the Wellcome Sanger Institute, and has over 20 years’ experience in genomics and cancer therapeutics.
Mathew is the Sanger Scientific Lead for Open Targets, which aims to use genome-scale experiments and analysis to evaluate new therapeutic targets.
Mathew performs CRISPR-Cas9 genetic screens in cancer cells to identify new drug targets, which led to the discovery of Werner Syndrome helicase as a synthetic-lethal target in microsatellite unstable cancers.  He is also the developer of leading, widely-used cancer therapeutics resources including DepMap and GDSC.
Mathew completed his PhD in 2005 in the laboratory of Richard Marais at The Institute of Cancer Research (London, UK), where he was involved in the discovery and characterisation of BRAF as a human cancer gene.

Co-Founder

Emile is a professor of medical oncology and Senior Group Leader at the Netherlands Cancer Institute and Oncode Institute.
Emile is a former Chairman of the board of Cancer Core Europe, a collaboration of 7 excellent comprehensive cancer centres.
Emile is the founder of multiple precision medicine programs, and is a global leader in translational research with an emphasis on genetics, tumour organoids and immunology.
Until 2021, Emile served as executive medical director of the Netherlands Cancer Institute. He is also an independent, non-executive board member of Sanofi, is co-founder and serves on the non-executive board of the Hartwig Medical Foundation.

Reach Out